Clinical trial
Safety Study of Seneca Valley Virus in Patients With Solid Tumors With…
NCT00314925 · Neotropix, Industry · Unknown status
Key facts
| NCT number | NCT00314925 |
|---|---|
| Title | Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features |
| Official title | Phase I Dose-Escalation Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Patients With Advanced Solid Tumors With Neuroendocrine Features |
| Lead sponsor | Neotropix, Industry |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoid, Neuroendocrine |
| Intervention type | Drug |
| Interventions | Seneca Valley Virus (biological agent) |
| Enrollment | 60 |
| Start date | Apr 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Apr 17, 2006 |
| Last update posted | Feb 25, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: